Entropy Neurodynamics Amends Constitution to Set 10% Employee Incentive Plan Cap Following AGM Approval

Sonal Goyal

13 November 2026 10:39 AM AEDT

Entropy Neurodynamics Amends Constitution to Set 10% Employee Incentive Plan Cap Following AGM Approval

Image Source: Krish Capital Pty Ltd

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Entropy Neurodynamics (ASX:ENP), a clinical-stage biotechnology company developing precision controlled psychedelic therapies, has amended its Constitution to reflect changes to employee share scheme provisions under Part 7.12 of the Corporations Act 2001 (Cth), following shareholder approval at the company's Annual General Meeting held on 12 November 2026.

Key Points

The Constitution has been amended to reflect changes to employee share scheme provisions under Part 7.12 of the Corporations Act 2001 (Cth).
A new clause 2.15 has been inserted, setting the issue cap for the Employee Incentive Plan at 10% under section 1100V(2) of the Corporations Act 2001 (Cth).
Shareholder approval for the amendments was obtained at the Annual General Meeting held on 12 November 2026.
The amended Constitution has been attached to the filing in accordance with ASX Listing Rule 15.4.2.

Constitutional Amendment Details

Entropy Neurodynamics disclosed that amendments to its Constitution have been made to reflect changes to employee share scheme provisions under Part 7.12 of the Corporations Act 2001 (Cth). The key amendment is the insertion of clause 2.15, which establishes the issue cap for the company's Employee Incentive Plan at 10% for the purposes of section 1100V(2) of the Corporations Act 2001 (Cth). The amended Constitution has been attached to the company's filing in accordance with ASX Listing Rule 15.4.2, the company stated.

Annual General Meeting Approval on 12 November 2026

According to the filing, the constitutional amendments follow shareholder approval obtained at the company's Annual General Meeting held on 12 November 2026. The amendments were authorised by the Board of Entropy Neurodynamics. The company is based in Melbourne, Australia, and describes itself as a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs.

Company's Lead Program and Clinical Background

The filing states that Entropy Neurodynamics' lead program, TRP-8803, is a proprietary formulation of IV-infused psilocin, described as the active metabolite of psilocybin. According to the filing, TRP-8803 has potential to significantly reduce the time to onset of the psychedelic state, control the depth and duration of the psychedelic experience, and reduce the overall duration of the intervention. The company disclosed that development of TRP-8803 follows a number of Phase 2a clinical trials using oral psilocybin for the treatment of Binge Eating Disorder, Irritable Bowel Syndrome, and Fibromyalgia.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.